Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 14/20 | 1.00 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.62 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2337394 | 0.92 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1NPC1MAPT | |
| Senicapoc SCHEMBL1443805 | 0.92 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1NPC1MAPT | |
| SCHEMBL13928001 | 0.90 | KCNN4 (0.81) | KCNN4KCNE1KCNQ1SMN1; SMN2 | |
| SCHEMBL18782528 | 0.90 | KCNN4 (0.81) | KCNN4KCNE1KCNQ1ALDH1A1HTT | |
| SCHEMBL18782529 | 0.87 | KCNN4 (0.75) | KCNN4KCNE1KCNQ1NPC1RAB9A | |
| SCHEMBL12812142 | 0.85 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1CES2CES1 | |
| SCHEMBL12811863 | 0.85 | KCNN4 (0.86) | KCNN4KCNE1KCNQ1ALDH1A1NPC1 | |
| SCHEMBL1443978 | 0.85 | KCNN4 (1.00) | KCNN4KCNE1KCNQ1CES2CES1 | |
| SCHEMBL18782527 | 0.82 | KCNN4 (0.68) | KCNN4KCNE1KCNQ1ALDH1A1MEN1 | |
| SCHEMBL12811865 | 0.82 | KCNN4 (0.68) | KCNN4KCNE1KCNQ1ALDH1A1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003004010-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR OBTAINING IMMUNE REGULATION | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-01-16 | — | — | WO | claimed |
| US-10179115-B2 | Methods for treating malaria using potassium channel inhibitors | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2019-01-15 | — | — | US | disclosed |
| US-20180042872-A1 | METHODS FOR TREATING MALARIA USING POTASSIUM CHANNEL INHIBITORS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-02-15 | — | — | US | disclosed |
| US-20180042872-A1 | METHODS FOR TREATING MALARIA USING POTASSIUM CHANNEL INHIBITORS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2018-02-15 | — | — | US | disclosed |
| WO-2017070536-A1 | METHODS AND AGENTS FOR TREATING DISEASES | ANGION BIOMEDICA CORP. (US) | 2017-04-27 | — | — | WO | disclosed |
| US-9428568-B2 | Compositions and methods for modulating cell-cell fusion via intermediate-conductance calcium-activated potassium channels | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-30 | — | — | US | disclosed |
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | YALE UNIVERSITY (US) | 2011-12-08 | — | — | US | disclosed |
| EP-2358750-A2 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | Boehringer Ingelheim International GmbH (DE) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011034860-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| WO-2010053584-A2 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| US-20100056637-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20090036538-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2009-02-05 | — | — | US | disclosed |
| EP-1861356-A1 | IMINES AS ION CHANNEL MODULATORS | Icagen, Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1158971-B1 | GARDOS CHANNEL ANTAGONISTS | ICAGEN INC (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | ICAGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | ICAGEN, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2007075849-A2 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | ICAGEN, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060178346-A1 | Imines as ion channel modulators | ICAGEN, INC. (US) | 2006-08-10 | — | — | US | disclosed |
| WO-2006084031-A1 | IMINES AS ION CHANNEL MODULATORS | ICAGEN, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2003004010-A1 | CARBONYLAMINO DERIVATIVES USEFUL FOR OBTAINING IMMUNE REGULATION | POSEIDON PHARMACEUTICALS A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185209-A1 | Treatment methods using triaryl methane compounds | KCNH3, KCNH2, KCNJ2 | KCNN4 37/4885KCNE1 20/4885KCNQ1 23/4885 |
| US-20090036538-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | KCNH3, KCNH2, KCNJ2 | KCNN4 37/4885KCNE1 20/4885KCNQ1 23/4885 |
| US-20110300152-A1 | COMPOSITIONS AND METHODS FOR MODULATING CELL-CELL FUSION VIA INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS | KCNN3, KCNN4, KCNMA1 | KCNN4 2/4885KCNE1 68/4885KCNQ1 27/4885 |
| US-20060178346-A1 | Imines as ion channel modulators | KCNN1, KCNN3, KCNN2 | KCNN4 4/4885KCNE1 27/4885KCNQ1 73/4885 |
| US-20180042872-A1 | METHODS FOR TREATING MALARIA USING POTASSIUM CHANNEL INHIBITORS | KCNN1, KCNN2, KCNN3 | KCNN4 10/4885KCNE1 41/4885KCNQ1 5/4885 |
| US-10179115-B2 | Methods for treating malaria using potassium channel inhibitors | KCNN1, KCNN2, KCNN3 | KCNN4 10/4885KCNE1 41/4885KCNQ1 5/4885 |
| US-20100056637-A1 | TREATMENT METHODS USING TRIARYL METHANE COMPOUNDS | LTC4S, LTB4R2, CYSLTR2 | KCNN4 2132/4885KCNE1 2203/4885KCNQ1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.